A study assessed the composition of γδ T cell subgroups in AML subjects of diverse clinical statuses by evaluating the immune checkpoint co-inhibitor T cell immunoglobulin and immunoreceptor tyrosine-based (TIGIT) inhibitory (motif domain) and its co-stimulatory receptor CD226 [77]. This evidence concerns the gene TIGIT and acute myeloid leukemia.